Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor Y in cardiac fibrosis

Diabetes

Volumn 57, Issue 9, 2008, Pages 2470-2479

  Caglayan, Evren ^a,b   Stauber, Bradley ^a   Collins, Alan R ^c   Lyon, Christopher J ^c   Yin, Fen ^a   Liu, Joey ^c   Rosenkranz, Stephan ^b   Erdmann, Erland ^b   Peterson, Leif E ^d   Ross, Robert S ^e   Tangirala, Rajendra K ^a   Hsueh, Willa A ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Division of Diabetes   (United States)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANGIOTENSIN II; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN, MOUSE; ANTIDIABETIC AGENT; VASOCONSTRICTOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; MACROPHAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE; ANIMAL; BLOOD; C57BL MOUSE; CARDIOMEGALY; CHEMOTAXIS; DBA MOUSE; DRUG EFFECT; FEMALE; FIBROSIS; GENETICS; HEART MUSCLE; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ADIPONECTIN; ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; CHEMOTAXIS; FEMALE; FIBROSIS; HYPOGLYCEMIC AGENTS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; MYOCARDIUM; MYOCYTES, CARDIAC; PPAR GAMMA; THIAZOLIDINEDIONES; VASOCONSTRICTOR AGENTS;

EID: 52749098189     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-0924     Document Type: Article

References (48)

1. Asbun J, Villarreal FJ: The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 47:693-700, 2006
2. Deedwania PC: The progression from hypertension to heart failure. Am J Hypertens 10:280S-288S, 1997
3. Kai H, Kuwahara F, Tokuda K, Imaizumi T: Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 28:483-490, 2005
4. Weber KT: Are myocardial fibrosis and diastolic dysfunction reversible in hypertensive heart disease? Congest Heart Fail 11:322-325, 2005
5. Diez J: Profibrotic effects of angiotensin II in the heart: a matter of mediators. Hypertension 43:1164-1165, 2004
6. Dostal DE: Regulation of cardiac collagen: angiotensin and cross-talk with local growth factors. Hypertension 37:841-844, 2001
7. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 40:1414-1421, 2002
8. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al., the SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 327:669 -677, 1992
9. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, the Randomized Aldactone Evaluation Study Investigators: The effect ofspironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709-717, 1999
10. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M: The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113:1424-1433, 2006
11. Collins AR, Schnee J, Wang W, Kim S, Fishbein MC, Bruemmer D, Law RE, Nicholas S, Ross RS, Hsueh WA: Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J Am Coll Cardiol 43:1698-1705, 2004
12. Ashizawa N, Graf K, Do YS, Nunohiro T, Giachelli CM, Meehan WP, Tuan TL, Hsueh WA: Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. J Clin Invest 98:2218-2227, 1996
13. Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC, Fleck E, Hsueh WA: Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation 96:3063-3071, 1997
14. Subramanian V, Krishnamurthy P, Singh K, Singh M: Lack of osteopontin improves cardiac function in streptozotocin-induced diabetic mice. 292: H673-H683, 2007
15. Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA: Obesity, peroxi- some proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol 26:28-40, 2006
16. Wakino S, Law RE, Hsueh WA: Vascular protective effects by activation of nuclear receptor PPARgamma. J Diabetes Complications 16:46-49, 2002
17. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer HB, Jr, Gonzalez FJ: Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 22:2607-2619, 2002
18. Chen J, Kubalak SW, Minamisawa S, Price RL, Becker KD, Hickey R, Ross J, Jr, Chien KR: Selective requirement of myosin light chain 2v in embryonic heart function. J Biol Chem 273:1252-1256, 1998
19. Jones JR, Shelton KD, Guan Y, Breyer MD, Magnuson MA: Generation and functional confirmation of a conditional null PPARgamma allele in mice. Genesis 32:134-137, 2002
20. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I: Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 8:265-277, 1999
21. Daugherty A, Cassis L: Chronic Angiotensin II Infusion Promotes Athero-genesis in Low Density Lipoprotein Receptor -/- Mice. Ann N Y Acad Sci 892:108-118, 1999
22. Daugherty A, Manning MW, Cassis LA Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105:1605-1612, 2000
23. Weiss D, Kools JJ, Taylor WR: Angiotensin II-Induced Hypertension Accelerates the Development of Atherosclerosis in ApoE-Deficient Mice. Circulation 103:448-454, 2001
24. Xiao G, Mao S, Baumgarten G, Serrano J, Jordan MC, Roos KP, Fishbein MC, MacLellan WR: Inducible activation of c-Myc in adult myocardium in vivo provokes cardiac myocyte hypertrophy and reactivation of DNA synthesis. Circ Res 89:1122-1129, 2001
25. Ishikawa S, Fattal GA, Popiewicz J, Wyatt JP: Functional morphometry of myocardial fibers in cor pulmonale. Am, Rev RespirDis 105:358-367, 1972
26. Satoh H, Nguyen MT, Trujillo M, Imamura T, Usui I, Scherer PE, Olefsky JM: Adenovirus-mediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats. Diabetes 54:1304-1313, 2005
27. Sambrano GR, Fraser I, Han H, Ni Y, O'Connell T, Yan Z, Stull JT: Navigating the signalling network in mouse cardiac myocytes. Nature 420:712-714, 2002
28. Henderson SA, Goldhaber JI, So JM, Han T, Motter C, Ngo A, Chantawansri C, Ritter MR, Friedlander M, Nicoll DA, Frank JS, Jordan MC, Roos KP, Ross RS, Philipson KD: functional adult myocardium in the absence of Na+-Ca2+ exchange: cardiac-specific knockout of NCX1. Circ Res 95: 604-611, 2004
29. Takata Y, Chu V, Collins AR, Lyon CJ, Wang W, Blaschke F, Bruemmer D, Caglayan E, Daley W, Higaki J, Fishbein MC, Tangirala RK, Law RE, Hsueh WA: Transcriptional repression of ATP-binding cassette transporter A1 gene in macrophages: a novel atherosclerotic effect of angiotensin II. Circ Res 97:e88-e96, 2005
30. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, Kumada M, Sato K, Schiekofer S, Ohashi K, Funahashi T, Colucci WS, Walsh K: Adiponectin-mediated modulation ofhypertrophic signals in the heart. Nat Med 10:1384-1389, 2004
31. Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA: Over-expression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res 95:637-644, 2004
32. Zhao W, Ahokas RA, Weber KT, Sun Y: ANG Il-induced cardiac molecular and cellular events: role of aldosterone. Am, J Physiol Heart Circ Physiol 291:H336-H343, 2006
33. Babaev VR, Yancey PG, Ryzhov SV, Kon V, Breyer MD, Magnuson MA, Fazio S, Linton MF: Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. 25:1647-1653, 2005
34. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11:861-866, 2005
35. Caglayan E, Blaschke F, Takata Y, Hsueh WA: Metabolic syndrome-interdependence of the cardiovascular and metabolic pathways. Curr Opin Pharmacol 5:135-142, 2005
36. Lago RM, Singh PP, Nesto RW: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazo-lidinediones: a meta-analysis of randomised clinical trials. Lancet 370: 1129-1136, 2007
37. Schnee JM, Hsueh WA: Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc Res 46:264-268, 2000
38. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM: Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45:356-362, 2005
39. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T, Komuro I: Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105:1240-1246, 2002
40. Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM: Cardiomyocyte-specific knockout and agonist of peroxisome proliferator activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res 97:372-379, 2005
41. St. John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, Patel J, Freed M: A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 25:2058-2064, 2002
42. Horio T, Suzuki M, Suzuki K, Takamisawa I, Hiuge A, Kamide K, Takiuchi S, Iwashima Y, Kihara S, Funahashi T, Yoshimasa Y, Kawano Y: Pioglita-zone improves left ventricular diastolic function in patients with essential hypertension. Am, J Hypertens 18:949-957, 2005
43. Kawano H, Cody RJ, Graf K, Goetze S, Kawano Y, Schnee J, Law RE, Hsueh WA: Angiotensin II enhances integrin and alpha-actinin expression in adult rat cardiac fibroblasts. Hypertension 35:273-279, 2000
44. Trueblood NA, Xie Z, Communal C, Sam F, Ngoy S, Liaw L, Jenkins AW, Wang J, Sawyer DB, Bing OH, Apstein CS, Colucci WS, Singh K: Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res 88:1080-1087, 2001
45. Matsui Y, Jia N, Okamoto H, Kon S, Onozuka H, Akino M, Liu L, Morimoto J, Rittling SR, Denhardt D, Kitabatake A, Uede T: Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 43:1195-1201, 2004
46. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K, Law RE, Hsueh WA: Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 112:1318-1331, 2003
47. Oyama Y, Akuzawa N, Nagai R, Kurabayashi M: PPARgamma ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells. Circ Res 90:348-355, 2002
48. Kintscher U, Goetze S, Wakino S, Kim S, Nagpal S, Chandraratna RA, Graf K, Fleck E, Hsueh WA, Law RE: Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol 401:259-270, 2000